What is Apogee Therapeutics Earnings Power Value (EPV)?
As of Mar24, Apogee Therapeutics's earnings power value is $16.23. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Apogee Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Apogee Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apogee Therapeutics Earnings Power Value (EPV) Chart
|
Apogee Therapeutics Annual Data
|
|
Trend |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
|
Apogee Therapeutics Quarterly Data
|
|
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
Competitive Comparison of Apogee Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Apogee Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apogee Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Apogee Therapeutics's Earnings Power Value (EPV) falls into.
Apogee Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Apogee Therapeutics (Apogee Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Executives
| Mark C. Mckenna |
director |
400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807 |
| Nimish P Shah |
director |
7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018 |
| Jane Henderson |
officer: Chief Financial Officer |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
| Peter Evan Harwin |
director |
2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
| Jones William A Jr |
director |
NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421 |
| Fairmount Funds Management Llc |
director |
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
| Michael Thomas Henderson |
director, officer: Chief Executive Officer |
421 KIPLING STREET, PALO ALTO CA 94301 |
| Fairmount Healthcare Fund L.p. |
director |
2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
| Fairmount Healthcare Fund Ii L.p. |
director |
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
| Tomas Kiselak |
director |
2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
| Jennifer A. Fox |
director |
C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036 |
| Andrew Gottesdiener |
director |
3340 HILLVIEW AVE, PALO ALTO CA 94304 |
| Fairmount Healthcare Co-invest Ii L.p. |
director |
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
| Carl Dambkowski |
officer: Chief Medical Officer |
221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453 |
Apogee Therapeutics (Apogee Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APGE has been successfully added to your